Science Speaks: No Evidence Supporting Autism Risk in IVF-Generated Offspring

2023-11-27

In a recent publication in JAMA Network Open, a significant study explores the intricate connection between infertility, fertility treatments, and the development of Autism Spectrum Disorder (ASD) in children. The research, conducted in Ontario, spans a…

In a recent publication in JAMA Network Open, a significant study explores the intricate connection between infertility, fertility treatments, and the development of Autism Spectrum Disorder (ASD) in children. The research, conducted in Ontario, spans a retrospective cohort from April 2006 to March 2018, incorporating administrative healthcare data from various sources, including the Better Outcomes Registry and Network (BORN) database, hospitalization records, outpatient visits, and emergency department data. ASD, characterized by abnormal brain development and typically manifesting within 18 months of life, is known to be influenced by a combination of hereditary and environmental factors. Prenatal risk factors include infertility, maternal metabolic and inflammatory variables, and offspring epigenetic alterations. However, prior studies often overlooked the role of infertility and mediating effects in understanding the relationship between ASD and its potential precursors. The study design involved categorizing conception modes into unaided, subfertility, intrauterine insemination (IUI) or ovulation induction (OI), and intracytoplasmic sperm injections (ICSI) or in vitro fertilization (IVF). Researchers employed multivariable Cox regression modeling, adjusting for various covariates, to determine adjusted hazard ratios (aHRs). Causal mediation analyses were conducted to assess the impact of pregnancy outcomes such as preeclampsia, cesarean birth, multifetal pregnancies, severe neonatal morbidities, and preterm birth on ASD risk. The results, based on a cohort of 1,370,152 infants, indicated an ASD incidence of 1.9 per 1,000 individual years for those born through unaided conception. Notably, children born to infertile individuals demonstrated a marginally higher ASD risk, irrespective of whether fertility treatments were administered. The study highlighted the significant role of adverse pregnancy outcomes in mediating ASD risk, particularly after ICSI or IVF. In conclusion, the findings suggest that the underlying factor contributing to the link between parental infertility and ASD in children might be infertility itself rather than fertility treatments. As a result, the study advocates for ongoing efforts to reduce multifetal pregnancies following fertility treatments and emphasizes the need for tailored care plans for subfertile individuals and those undergoing fertility treatment. This comprehensive research provides valuable insights into the complex dynamics of ASD development, paving the way for more targeted and effective care strategies for affected families. Sources: https://www.news-medical.net/news/20231121/Association-between-infertility-and-autism-spectrum-disorder-risk-among-children.aspx Maria P. Velez, MD, PhD, et al., (2023) Infertility and Risk of Autism Spectrum Disorder in Children, JAMA Network Open., doi:10.1001/jamanetworkopen.2023.43954

How IVF child-health evidence affects IVF planning

This topic is most useful when it is connected to a specific treatment decision. Patients should not treat general fertility information as a replacement for diagnosis, but it can help them ask better questions before choosing a protocol, clinic, or travel date. A practical consultation should identify the main barrier to pregnancy, the tests that are still missing, the options that are realistic, and the steps that are optional rather than urgent.

For IVF Turkey patients, the planning conversation should include ovarian reserve, sperm quality, previous pregnancy history, prior IVF or IUI attempts, medication use, surgery history, and any known genetic or family-history concerns. These details help the medical team decide whether the next step is standard IVF, ICSI, embryo freezing, embryo transfer, male-factor review, genetic counseling, or another preparation step before treatment begins.

International patients should also connect the medical plan with logistics. Treatment in Turkey may involve tests before travel, ultrasound monitoring, medication timing, egg retrieval, fertilization updates, embryo development, transfer planning, and follow-up after returning home. Patients should confirm the expected stay length, what records must be shared in advance, and how the clinic will communicate instructions during the cycle.

Questions to ask in consultation

  • Which test results are needed before the treatment protocol can be chosen?
  • Does this topic change embryo transfer timing, medication choice, or the need for extra testing?
  • Should male fertility, tubal status, or genetic history be reviewed before the cycle starts?
  • What costs are fixed, and which costs depend on medication, ICSI, genetic testing, freezing, or follow-up?
  • What symptoms, delays, or results should prompt the patient to contact the care team quickly?

Useful next steps include reviewing IVF cost in Turkey, understanding embryo transfer, and asking IVF Turkey for a case-specific review. Depending on the history, patients may also need low sperm count, varicocele and male fertility, genetic disorder screening, PGD embryo biopsy, egg freezing in Turkey, or IVF in Turkey for American patients.

The goal is to leave the consultation with a clear order of action: what to do now, what to monitor during treatment, what can wait, and how success or next steps will be evaluated. That order matters for patients who are trying to avoid unnecessary delay while still making a medically grounded decision.

Patients should also ask how the care team will measure progress after the first decision is made. For some couples, the next milestone is completing missing tests. For others, it is confirming medication response, fertilization, embryo quality, or pregnancy follow-up. Clear milestones make it easier to know whether the plan is working and when it should be adjusted.

This is especially important for patients traveling for care because every extra visit, medication change, or laboratory decision can affect timing and budget. A written plan should explain who to contact, which results need urgent review, and what information should be shared with the patient's local doctor after returning home.

Patients should leave the conversation knowing the next practical action: send records, repeat a test, schedule monitoring, adjust medication, plan travel, or wait for a defined result. That clarity is a stronger signal of useful care than a long list of optional add-ons.